Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer

AIMS: Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET‐positive gastric cancer. The aim of this study was to evaluate the potential pharmacokinetic (PK)‐based drug–drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X)....

全面介紹

Na minha lista:
書目詳細資料
發表在:Br J Clin Pharmacol
Main Authors: Zhang, Yilong, Kuchimanchi, Mita, Zhu, Min, Doshi, Sameer, Hoang, Tien, Kasichayanula, Sreeneeranj
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2016
主題:
Pharmacokinetics
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401968/
https://ncbi.nlm.nih.gov/pubmed/27966237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13179
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍